Table 4:
LV mass index | Model 1 n=72 |
Model 2 n=72 |
||
---|---|---|---|---|
β | p | β | P | |
MFR global | −1.8403 | 0.007 | −2.0874 | 0.008 |
Age, per year | 0.0894 | 0.49 | ||
Race/ethnicity | ||||
Non-Hispanic white | ref | Ref | ref | Ref |
Non-Hispanic black | 1.5479 | 0.49 | 1.7415 | 0.343 |
Hispanic | 3.6751 | 0.024 | 3.6076 | 0.013 |
Hypertension, yes v no | −0.4099 | 0.81 | ||
Diabetes, yes v. no | 1.076 | 065 | ||
HDL, per mg/dL | −0.0129 | 0.73 | ||
log triglycerides, per unit | −0.6970 | 0.72 | ||
RF or anti-CCP, yes v. no | 2.5564 | 0.082 | 2.4703 | 0.063 |
DAS28-CRP | ||||
DAS28-CRP<2.6 | Ref | Ref | ref | Ref |
DAS28-CRP 2.6-4.1 | 2.6664 | 0.12 | 2.3467 | 0.13 |
DAS28-CRP>4.1 | 4.3491 | 0.032 | 4.1895 | 0.022 |
HAQ, per unit | −1.9814 | 0.056 | −1.5833 | 0.062 |
Median IL-6, per unit | 0.4385 | 0.75 | ||
CAC score | ||||
CAC score zero | Ref | ref | ||
CAC score 1-99 | −1.2262 | 0.54 | ||
CAC score ≥100 | −0.3529 | 0.87 | ||
ACE-inhibitor use | 3.6773 | 0.075 | 4.6417 | 0.001 |
Statin use | 0.7441 | 0.71 | ||
Prob>F | 0.005 | <0.00001 | ||
Unadjusted R2 | 0.4437 | 0.4094 |
Model 1 covariates are derived from table 2 where any variable with a p<0.2 was included. BMI was not included due to collinearity with LVMI which is indexed by height. Model 2 is a reduced model that includes all of the covariates from Model 1 with p values < 0.2. RF: rheumatoid factor, CCP: cyclic citrullinated protein antibody, DAS: disease activity score, HDL: high density lipoprotein, CRP: C-reactive protein, IL-6: interleukin 6, MFR: myocardial blood flow reserve, CAC: coronary artery calcium.